

VIRALEZE™ relaunched by LloydsPharmacy in the UK

- **VIRALEZE™ has overnight been relaunched in the UK through LloydsPharmacy Online, with distribution to pharmacies to follow shortly**
- **LloydsPharmacy is one of the largest pharmacy chains in the UK with ~1,400 stores, and through its affiliated wholesale arm, AAH, also supplies over 14,000 independent UK pharmacies**

Melbourne, Australia; 30 June 2022: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that VIRALEZE™ nasal spray has been relaunched by LloydsPharmacy in the UK. Product has already been delivered to LloydsPharmacy's distribution centre.

LloydsPharmacy is one of the largest pharmacy groups in the UK, and its affiliated wholesale arm, AAH, is also one of the largest pharmaceutical wholesalers in the UK, supplying over 14,000 independent UK pharmacies.

In the UK, Starpharma will supply VIRALEZE™ exclusively to LloydsPharmacy/AAH under its existing sales and distribution agreement. LloydsPharmacy has approximately 1,400 UK pharmacies, based predominantly in community and health centre locations, including over 200 pharmacies in Sainsbury stores. The group employs more than 19,000 people and dispenses more than 150 million prescription items annually.

Dr Jackie Fairley, the CEO of Starpharma, said:

"We are delighted to relaunch Starpharma's innovative nasal spray, VIRALEZE™, in the UK through LloydsPharmacy's extensive online and retail network. VIRALEZE™ will be particularly useful in the winter cold and flu season given its broad-spectrum of activity against multiple cold and respiratory viruses. VIRALEZE™ is supported by multiple publications in peer-reviewed, international journals and was presented at leading, international antiviral conference, CROI, earlier this year."

VIRALEZE™ is registered in more than 30 countries, including the UK, and Starpharma continues to pursue registration and commercialisation in multiple other countries.

LloydsPharmacy

The LloydsPharmacy group incorporates a number of market leading UK healthcare businesses across retail, digital, homecare and wholesale, including LloydsPharmacy, John Bell & Croyden and wholesaler, AAH Pharmaceuticals. LloydsPharmacy has around 1,400 pharmacies across the UK. These are based predominantly in community and health centre locations and include over 200 LloydsPharmacy in Sainsbury's stores. The group employs over 19,000 employees and dispenses more than 150 million prescription items annually.

AAH is a leading distributor of pharmaceutical and healthcare products serving pharmacies, hospitals and doctors in the UK. AAH is the largest community pharmacy network and pharmaceutical wholesaler delivering over 15 million items per week to more than 14,000 pharmacies and other organisations.

VIRALEZE™ Nasal Spray

VIRALEZE™ is a nasal spray that physically traps and blocks cold/respiratory viruses in the nasal cavity. VIRALEZE™ is applied in the nose where it forms a physical moisture barrier between viruses and the nasal mucous membrane that traps and blocks virus.

VIRALEZE™ is registered as a medical device in more than 30 countries and is available in certain markets online. Product claims may differ by market. Starpharma markets VIRALEZE™ via commercial arrangements in countries in Europe, Asia, and the Middle East.

VIRALEZE™ was developed with the support of \$1 million in funding by the Australian Government's Medical Research Future Fund (MRFF) Biomedical Translation Bridge (BTB) Program, with support from UniQuest.

VIRALEZE™ is not approved for sale or supply in Australia.

About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for respiratory viruses, DEP® drug delivery and VivaGel®. Starpharma has developed VIRALEZE™, an antiviral nasal spray that is registered for sale in >30 countries, and available outside Australia in certain markets online. VIRALEZE™ is not approved for sale or supply in Australia. SPL7013 is utilised in approved products - the VivaGel® condom and VivaGel® BV. VivaGel® products have been licensed in >160 countries, are registered in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, South Africa, Australia and New Zealand.

As a leading company in dendrimer-based drug delivery, Starpharma's proprietary drug delivery platform technology, DEP®, is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP® versions of existing drugs, particularly in the area of anti-cancer therapies. DEP® partnerships include oncology programs with AstraZeneca, with Merck & Co., Inc., in the area of Antibody Drug Conjugates (ADCs), with Chase Sun in the area of anti-infectives and other world leading pharmaceutical companies. Starpharma's partnered DEP® programs have the potential to generate significant future milestones and royalties.

Starpharma.com | [Twitter](#) | [LinkedIn](#)

Media: Sumit Media

Grant Titmus
Mob: +61 419 388 161
grant@sumitmedia.com.au

Starpharma Holdings Limited

Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067

Disclosure

This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.



Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.